Metformin plus Clomiphene Citrate versus Gonadotropins in Clomiphene Citrate- Resistant Polycystic Ovary Syndrome
Abstract
Introduction: Clomiphene citrate (CC) is the first-line pharmacological therapy for ovulation induction in polycystic ovary syndrome (PCOS). However, 15%-40% of patients show CC-resistance. Different drugs and drug combinations were in trial to overcome resistance.
Aim of the study: comparison between the metformin plus CC and low dose exogenous follicle stimulating hormone (FSH) in CC-resistant PCOS.
Subjects and methods: A prospective comparative trial was carried out for a period of 36 months (between June 2019 to June 2022) with ovulation induction period of 3 months. It included 40 patients with CC- resistance. They were divided into 2 groups. The first received metformin plus CC and the second received low dose exogenous FSH for 3 months. The cycles were monitored by transvaginal sonography (TVS), starting on the 11th day of the cycle. The primary outcome was the successful ovulation, and the secondary outcome was the detection of pregnancy sac (clinical pregnancy).
Results: Metformin plus CC succeeded to produce a higher rate of ovulation. However, gonadotrophins are more effective as it produced a significantly higher rate in the first cycle (45.0% vs. 15%). However, there were no significant differences at the second and third cycles. The overall ovulation rate was 60% and 80.0% in metformin-CC group compared to gonadotrophin group. The clinical pregnancy rate was 25% and 15% in groups I and II, respectively (p value >0.05). Complications were confined to…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.